Pharmabiz carries and editorial,

India offers a unique opportunity for conducting clinical trials with a large and diverse patient pool along with considerable low trial costs. The acceptability of Indian pharmaceutical industry as a reliable source for these services will, however, depend on the quality of services provided by the companies. And it is here the Indian pharmaceutical industry and the regulatory bodies have to be extremely vigilant.